Pentixapharm AG, together with its U. S. subsidiary Pentixapharm Inc., is a research-driven radiopharmaceutical and precision oncology company focused on the preclinical and clinical development, as well as manufacturing, of innovative theranostic agents. Its lead drug candidate pair, Pentixa For/ Pentixa Ther, along with an antibody-based pipeline, targets the CXCR4 receptor. Target indications include hematologic and solid cancers, as ...